Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder Psychedelics Investing
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® in Canada Pharmaceutical Investing
DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan Pharmaceutical Investing
Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study Geography
Goodness Growth Holdings Announces Departure of General Counsel & Chief Compliance Officer Psychedelics Investing
